AI Model Mines Fungal Chemistry for New Diabetes Drug Leads

A team of computational chemists in Thailand has unveiled a machine learning framework that can scan tens of thousands of molecules and flag the ones most likely to switch on a receptor central to human metabolism. The tool, called Meta-iPPAR, was built to predict whether a compound will act as an agonist of peroxisome proliferator-activated receptor gamma, or PPAR-γ, a nuclear receptor that governs fat cell formation, glucose handling, lipid metabolism, and inflammation. Because PPAR-γ sits at the crossroads of so many metabolic processes, it has long been a prized target for drugs against type 2 diabetes and related disorders, yet its complicated pharmacology has made finding the right molecules a slow and expensive affair. The new study, published in the journal Molecular Diversity, describes how the researchers combined stacked machine learning, molecular docking, and molecular dynamics simulations into a single pipeline that takes a molecule’s chemical structure and returns a verdict on its likely activity.

The core of Meta-iPPAR is a stacking strategy, an ensemble technique in which several different machine learning algorithms are trained on the same data and a higher-level meta-model then learns how best to weigh their individual predictions. Rather than relying on a single classifier, the framework draws on a diverse set of molecular descriptors computed directly from SMILES strings, the compact text notation that encodes chemical structures. This multi-view representation allows the model to capture different aspects of a molecule’s character, from its topology and physicochemical properties to patterns of atoms and bonds. The authors, led by Phasit Charoenkwan of Chiang Mai University together with colleagues at Mahidol University, have used similar stacking approaches in previous work on antiviral peptides, ACE inhibitory peptides, and other bioactive molecules, and the new study extends that recipe into the small-molecule drug discovery arena.

The performance figures reported for Meta-iPPAR are striking. On an independent test set of compounds the model achieved an accuracy of 0.926, an area under the receiver operating characteristic curve of 0.965, and a Matthews correlation coefficient of 0.848. In practical terms, the model correctly classified more than nine out of ten compounds and showed a strong balance between sensitivity and specificity, with the MCC value indicating that its predictions were far better than chance even on a balanced problem. Metrics of this kind matter because drug discovery datasets are often skewed, and a model that simply predicts the majority class can look impressive while being useless. The combination of high AUC and high MCC suggests that Meta-iPPAR has genuine discriminative power rather than an inflated score driven by class imbalance.

What sets this work apart from many black-box machine learning studies is the emphasis on interpretability. The researchers applied SHAP analysis, a technique borrowed from game theory that assigns each molecular feature a contribution value for every prediction, allowing chemists to see which structural elements push a compound toward or away from PPAR-γ activation. Alongside this, the team carried out a scaffold analysis, breaking the active compounds down into their core molecular frameworks in the tradition of the Bemis-Murcko decomposition to identify chemotypes that recur among agonists. Together, these analyses revealed molecular features and structural motifs associated with receptor activation, giving medicinal chemists actionable design rules rather than an opaque probability score. This kind of transparency is increasingly demanded in computational drug discovery, where regulators and researchers alike want to understand why a model makes its calls.

To demonstrate the framework’s real-world utility, the team turned Meta-iPPAR loose on a large library of natural products. More than 36,000 compounds from the Natural Products Atlas, a curated database of microbially derived molecules, were screened through the model. From this virtual haystack, three fungal-derived candidates emerged as the most promising hits. The choice of a natural products library is significant: compounds made by fungi and other microbes have evolved to interact with biological targets and have historically been an extraordinarily rich source of drugs, yet they remain underexplored relative to synthetic libraries because of the difficulty of sourcing and characterizing them.

The three candidates did not rest on the machine learning prediction alone. The researchers subjected them to molecular docking, computationally fitting each molecule into the ligand-binding domain of PPAR-γ to see how and where it would sit within the receptor’s pocket. They then ran molecular dynamics simulations lasting 300 nanoseconds for each candidate, watching how the protein-ligand complexes behaved over time in a simulated watery environment. Stable binding conformations persisted throughout the simulations, and the ligands maintained favorable interactions with key residues in the ligand-binding domain. Crucially, the behavior of the predicted agonists was comparable to that of known PPAR-γ agonists and co-crystal ligands whose binding modes have been determined experimentally, lending credibility to the computational hits.

The biology behind the target explains why so much effort is being invested. PPAR-γ is the receptor engaged by the thiazolidinedione class of antidiabetic drugs such as pioglitazone, which improve insulin sensitivity but carry side effects including weight gain and cardiovascular concerns. Structural studies have shown that full agonists stabilize one conformation of the receptor’s activation helix, while partial agonists achieve beneficial effects through alternative binding modes, potentially offering a better therapeutic profile. Recent research has also focused on ligands that block the phosphorylation of a specific serine residue on the receptor, a mechanism linked to insulin resistance without the classical agonist side effects. A reliable computational filter for agonist activity could therefore accelerate the search for next-generation PPAR-γ modulators with improved safety margins.

Meta-iPPAR also arrives amid a broader wave of machine learning tools aimed at this receptor. Other groups have recently described predictors such as PPGBioPred and PGMP_v1, and integrated virtual screening campaigns combining fragment molecular orbital calculations, docking, and dynamics have been used to find partial agonists for type 2 diabetes. The Thai team’s contribution is the stacking architecture paired with interpretability and a full structure-based validation chain, a combination they argue makes the framework particularly suitable for the early stages of a drug development pipeline. The model and all underlying data have been made publicly accessible through a web interface, lowering the barrier for other laboratories to apply or benchmark it.

The authors are careful to note the limits of what has been achieved. The three fungal candidates remain computational predictions, and the study’s conclusions call for future experimental validation and biological evaluation to confirm whether the molecules truly activate PPAR-γ in cells and animals. Even so, the work illustrates a template that is rapidly becoming standard in early drug discovery: a fast, interpretable machine learning model to triage enormous chemical libraries, followed by docking and dynamics to interrogate the survivors at atomic resolution. If the fungal hits survive laboratory testing, Meta-iPPAR will have demonstrated not just a clever algorithm but a shortcut from database to drug lead, one that could compress years of trial-and-error screening into weeks of computation.

Subject of Research: Interpretable machine learning and molecular simulation for predicting PPAR-γ agonists

Article Title: Interpretable QSAR modelling for PPAR-γ agonist prediction by integrating a stacking strategy, docking, and MD simulations

Article References: Charoenkwan, P., Meewan, I., Schaduangrat, N., & Shoombuatong, W. (2026). Interpretable QSAR modelling for PPAR-γ agonist prediction by integrating a stacking strategy, docking, and MD simulations. Molecular Diversity. https://doi.org/10.1007/s11030-026-11700-5

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11700-5

Keywords: PPAR-gamma, machine learning, QSAR, stacking ensemble, virtual screening, molecular docking, molecular dynamics, SHAP interpretability, natural products, drug discovery, type 2 diabetes, fungal metabolites